by Plus Therapeutics | Jul 22, 2025 | GBM
Each year on World Brain Day, the World Federation of Neurology (WFN) shines a global spotlight on the importance of brain health and the burden of neurological disorders. In 2025, this important observance carries the theme “Brain Health for All Ages”,...
by Plus Therapeutics | Jul 21, 2025 | Uncategorized
Central nervous system (CNS) cancers—including aggressive diseases like glioblastoma (GBM) and leptomeningeal metastases (LM)—remain among the most challenging cancers to treat. Despite decades of research, treatment options remain limited, and very few therapies have...
by Plus Therapeutics | Jul 16, 2025 | GBM
As we continue to honor GBM Awareness Day, Plus Therapeutics is proud to spotlight new insights from our RESPECT-GBM Phase 2 clinical trial—research aimed at addressing the urgent need for better treatment options for patients with recurrent glioblastoma (GBM). In a...
by Plus Therapeutics | Jul 16, 2025 | GBM
Today marks GBM Awareness Day, an important opportunity to raise awareness about glioblastoma (GBM)—an aggressive and life-threatening brain cancer that continues to pose significant challenges for patients, families, and clinicians worldwide. At Plus Therapeutics, we...
by Plus Therapeutics | Jul 15, 2025 | LM
Plus Therapeutics is pleased to announce its participation in the upcoming Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference, taking place August 14–16, 2025, at the Baltimore Waterfront Marriott Hotel in...
Recent Comments